Latest Intelligence in Switzerland

Published within

« | ... | 5 | 6 | 7 | 8 | 9 | 10 | 11 | 12 | 13 | ... | » »|

Type Product title / description Pub Price
Expert View
Expert View

Licensing Week - August 9, 2002

Last week saw a flurry of licensing activity by Bristol-Myers Squibb, as the US-based big pharma extended its drug discovery relationships with Athersys and Exelixis. Genomics also featured heavily last week, as Pfizer, Oxagen, Fujisawa and Quark were all involved in genetic research deals. Finally, Serono signed another marketing deal, this time licensing rights to Genentech's Raptiva.<BR />

Published By Datamonitor
08 Aug 2002
Expert View
Expert View

Licensing Week - August 16, 2002

Last week's licensing news had a truly global feel, with companies from the US, the UK, mainland Europe and Japan getting in on the action. The week saw deals between; AstraZeneca and Xenogen; Crucell and GenVec; Takeda and Human Genome Sciences; Adolor and Eli Lilly; and Anadys and Roche.

Published By Datamonitor
15 Aug 2002
CommentWire
CommentWire

Credit Suisse: troubled waters

Two CSFB senior executives (and four ex-employees) have been suspended for charging excessive brokerage fees on newly-issued technology shares during the dotcom boom. The news comes at a bad time for parent Credit Suisse, which recently announced a higher than expected Q2 loss and is in the process of restructuring to salvage its ailing share price.

Published By Datamonitor
16 Aug 2002
CommentWire
CommentWire

Nestle: Hershey goes again

Rumors that Nestle intends to buy Hershey and thereby regain the US rights to the Kit Kat brand have been proved right after the Swiss food giant offered to pay $11.5 billion for the company. If the bid succeeds, Nestle will become the largest chocolate brand in the US. However, there is mounting opposition to the sale of this iconic US company.

Published By Datamonitor
27 Aug 2002
CommentWire
CommentWire

Novartis: Eastern European generics to bring multiple rewards

Buying Slovenia's Lek gives an East European footing to Novartis' already large generics business. Lower R&D costs there should allow Novartis to move into the higher value specialty generics segment. The acquisition also gives Novartis revenues from generic Augmentin, which, unlike its own version of the product, are not dogged by risk of litigation.

Published By Datamonitor
04 Sep 2002
CommentWire
CommentWire

Zurich Financial: taking desperate measures

Once seen as one of the world's strongest companies, Zurich Financial has been forced into a desperate share issue and job cuts by mistaken acquisitions and poor risk assessment. Although its short-term future looks volatile, there's strong growth set for insurance market that will help Zurich and its competitors in the long term.

Published By Datamonitor
06 Sep 2002
CommentWire
CommentWire

Luxury goods industry: future's looking good

Luxury goods manufacturers have been reporting mixed results for H1 2002 sales; the slow economy and the continuing weakness in tourism have impacted growth. However, industry players can feel optimistic about the steady growth in the number and value of mass affluent and high net worth consumers, which will provide a sound base to develop and grow the prestige market.

Published By Datamonitor
12 Sep 2002
CommentWire
CommentWire

Swiss: exceeding expected results

Swiss has delivered encouraging results well above the company forecasts given when the airline began in March of this year. Transatlantic travel has been particularly popular, but it remains to be seen if this will continue with the constant threat of US and Middle East conflicts.

Published By Datamonitor
16 Sep 2002
CommentWire
CommentWire

Credit Suisse: boardroom shuffling isn't enough

Lukas Muehlemann's departure from his twin roles at Credit Suisse was no surprise, given the company's plummeting share price and US probes into the allocation of hot stock offerings. But new management alone will not solve the bank's problems. The new joint CEOs - inside players John Mack and Oswald Gruebel - now need a new strategy.

Published By Datamonitor
25 Sep 2002
CommentWire
CommentWire

Kuehne & Nagel: positive moves

Kuehne & Nagel is continuing its growth strategy with another acquisition in Central America. As economic slowdown keeps freight growth down in the developed world, it makes sense for K&N to focus on less exploited markets to maintain its profit growth. At the same time, the move expands the Swiss firm's worldwide network still further.

Published By Datamonitor
27 Sep 2002

« | ... | 5 | 6 | 7 | 8 | 9 | 10 | 11 | 12 | 13 | ... | » »|

No help is available.